Evidence map›Paper›PMID 41845897›Full record

ArticleACS nano2026

The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles.

Chuan-En Lu, Kai Liu, Audrey Gallud, Viktoriia Meklesh, Lisbeth Thorup Ravnkilde, Juna Santos, Filipa Dias Louro, Tasso Miliotis, Marco A Alfonzo-Mendez, Joanna Rejman and 8 more

Abstract read
In one paragraph

Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Chuan-En LuAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.ORCID 0009-0001-1505-7910
Kai LiuAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.ORCID 0000-0002-3045-0809
Audrey GalludAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.ORCID 0000-0003-0283-4028
Viktoriia MekleshAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Lisbeth Thorup RavnkildeData Science & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Juna SantosAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Filipa Dias LouroAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Tasso MiliotisResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden.ORCID 0000-0003-4917-0724
Marco A Alfonzo-MendezAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Joanna RejmanAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Luca PanarielloDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm SE-171 77, Sweden.
Hanna M G BarrigaDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm SE-171 77, Sweden.
Molly M StevensDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm SE-171 77, Sweden.ORCID 0000-0002-7335-266X
Fredrik HöökDepartment of Physics, Division of Nano and Biophysics, Chalmers University of Technology, Gothenburg 41296, Sweden.ORCID 0000-0003-1994-5015
Marianna Yanez ArtetaAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Johan UlanderData Science & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Suzy JonesData Science & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Alan SabirshAdvanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.ORCID 0000-0001-5310-0281

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When introduced into biological systems, the function and biodistribution of lipid nanoparticles (LNPs) are affected by the biomolecular coronas they acquire. Corona composition is determined by the biophysical and chemical properties of the particles and the contents of the biofluids. Polyethylene glycol (PEG) polymers, anchored using lipids that partition into LNPs during formulation, are key to LNP stability in circulation. It is, however, not well-studied how different PEG-lipid anchors, with different acyl chain lengths, headgroup/linker chemistries, and desorption rates (PEG "shedding" from nanoparticles) can affect corona composition and LNP function. Here, we examined how common PEG-lipid anchors affect (1)

Indexed as

LipidsNanoparticlesPolyethylene GlycolsProtein CoronaAnimalsHumansLiposomesMiceMice, Inbred C57BLParticle SizeTissue DistributionLipid NanoparticlesLipidsLiposomesPolyethylene GlycolsProtein Coronalipid chemistrylipid nanoparticlemass spectroscopypolyethylene glycolprotein coronaRaman spectroscopy

Identifiers

PMID41845897
PMCPMC13288917

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.